Moderna Inc.
Moderna Reports Preliminary 2024 Financial Results and Provides 2025 Outlook
Summary
On January 13, 2025, Moderna, Inc. reported preliminary unaudited financial results for the fiscal year ended December 31, 2024. The company generated product sales of $3.0 to $3.1 billion and an ending cash balance of approximately $9.5 billion. Moderna updated its 2025 financial framework, projecting revenue between $1.5 to $2.5 billion, a reduction in cash cost expenses by $1.0 billion, and an ending cash balance of approximately $6.0 billion. Moderna also highlighted progress across its pipeline, including updates on respiratory vaccines, latent and other vaccines, oncology therapeutics, and rare disease therapeutics.
Profitelligence Alerts
Get alerts for MRNA
Be first to know when Moderna Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Official SEC Documents
Advertisement